Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab + FOLFOX/Bevacizumab in mCRC
NCT01418222Phase 2Completed
- Sponsor
- Genentech
- Start
- Sep 2011
- Primary completion
- Mar 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of onartuzumab in metastatic colorectal cancer (mCRC), sponsored by Genentech. Started Sep 2011; status: completed.
02
Drugs
onartuzumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01418222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01418222.